Stocks · News reference

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Aug 5, 2026, 1:30 PMVandana Singh

Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 8:32 PMBenzinga Newsdesk
Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.76) per share. This is a 93.47 percent increase over losses of $(11.64) per share from the same period last year.
Read original at benzinga
ENVB
SEC EDGARAug 14, 2026, 8:15 PMSEC EDGAR
8-K filing — Enveric Biosciences, Inc. (ENVB)
Filed: 2026-08-14 AccNo: 0001493152-26-038385 Size: 260 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
ENVB
BenzingaAug 5, 2026, 12:08 PMBenzinga Newsdesk
Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings Align With Previously Reported BRET Data
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay, which has been previously described in peer-reviewed scientific literature (Wang et al., 2022)1. The Promega
Read original at benzinga
ENVB